Early versus late intensification for patients with high-risk Hodgkin lymphoma - 3 Cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: Five-year results of a randomized trial on behalf of the GOELAMS Group

Cancer

Volumn 113, Issue 12, 2008, Pages 3323-3330

  Arakelyan, Nina ^a,b   Berthou, Christian ^c   Desablens, Bernard ^d   De Guibert, Sophie ^e   Delwail, Vincent ^f   Moles, Marie Pierre ^g   Quittet, Philippe ^h   Jais, Jean Philippe ^a   Colonna, Pierre ^a,b   Andrieu, Jean Marie ^a,b   Gastinne, Thomas ⁱ   Sénécal, Delphine ^j   Dugay, Jacqueline ^k   Lucas, Virginie ^l   Casassus, Philippe ^m   Ghandour, Christiane ⁿ   Rodon, Philippe ^o   Vilque, Jean Pierre ^p   Jardel, Henry ^q   Audhuy, Bruno ^r   Schoenwald, Michèle ^l   Maigre, Michel ^o   Maisonneuve, Hervé ^s   Flesch, Michel ^t   more..

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c BREST UNIVERSITY HOSPITAL   (France)

^d AMIENS UNIVERSITY HOSPITAL   (France)

^e RENNES UNIVERSITY HOSPITAL   (France)

^f POITIERS UNIVERSITY HOSPITAL   (France)

^g ANGERS UNIVERSITY HOSPITAL   (France)

^h MONTPELLIER UNIVERSITY HOSPITAL   (France)

ⁱ NANTES UNIVERSITY HOSPITAL   (France)

^j UNIVERSITY HOSPITAL OF TOURS   (France)

^k Hospital Center   (France)

^l Hopital de la Source   (France)

^m AVICENNE HOSPITAL   (France)

ⁿ Seavigne Polyclinic   (France)

^o Hospital Center   (France)

^p NONE   (France)

^q Hospital Center   (France)

^r Hospital Center   (France)

^s Hospital Center   (France)

^t Departmental Hospital Center   (France)

more..

Author keywords

Advanced stages; Chemotherapy; Hodgkin lymphoma; Intensification

Indexed keywords

BLEOMYCIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; METHYLPREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINBLASTINE; VINDESINE;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; EARLY INTERVENTION; FEMALE; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; INTENSIVE CARE; INTERMETHOD COMPARISON; LOW ENERGY RADIATION; LYMPH NODE IRRADIATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM MASS; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; COMBINED MODALITY THERAPY; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; LYMPHATIC IRRADIATION; MALE; METHYLPREDNISOLONE; PREDNISONE; TREATMENT OUTCOME; VINBLASTINE; VINCRISTINE;

EID: 57649129102     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23979     Document Type: Article

References (21)

1. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327:1478-1484.
2. Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol. 2003;21:607-614.
3. Gobbi PG, Levis A, Chisesi T, et al. ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol. 2005;23:9198-9207.
4. Canellos GP. Is there an effective salvage therapy for advanced Hodgkin's disease? Ann Oncol. 1991;2(suppl 1):1-7.
5. Longo DL, Duffey PL, Young RC, et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol. 1992;10:210-218.
6. Canellos GP, Petroni GR, Barcos M, et al. Etoposide, vinblastine, and doxorubicin: an active regimen for the treatment of Hodgkin's disease in relapse following MOPP. Cancer and Leukemia Group B. J Clin Oncol. 1995;13:2005-2011.
7. Ferme C, Bastion Y, Lepage E, et al. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. Ann Oncol. 1995;6:543-549.
8. Tourani JM, Levy R, Colonna P, et al. High-dose salvage chemotherapy without bone marrow transplantation for adult patients with refractory Hodgkin's disease. J Clin Oncol. 1992;10:1086-1094.
9. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet. 1993;341:1051-1054.
10. Schmitz N, Glass B, Dreger P, et al. High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease. Ann Hematol. 1993;66:251-256.
11. Colwill R, Crump M, Couture F, et al. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol. 1995;13:396-402.
12. Vigouroux S, Milpied N, Andrieu JM, et al. Front-line high-dose therapy with autologous stem cell transplantation for high risk Hodgkin's disease: comparison with combined-modality therapy. Bone Marrow Transplant. 2002;29:833-842.
13. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971;31:1860-1861.
14. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998;339:1506-1514.
15. Federico M, Bellei M, Brice P, et al. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. J Clin Oncol. 2003;21:2320-2325.
16. Horning SJ, Hoppe RT, Breslin S, et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol. 2002;20:630-637.
17. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003;348:2386-2395.
18. Behringer K, Diehl V. Twenty-five years clinical trials of the German Hodgkin Study Group (GHSG). Eur J Haematol. 2005;75(suppl):21-25.
19. Gianni AM, Rambaldi A, Zinzani P, et al. Comparable 3-year outcome after ABVD or BEACOPP first-line chemotherapy, plus preplanned high-dose salvage, in advanced Hodgkin lymphoma (HL): a randomized trial of the Michelangelo, GITIL and HL cooperative groups [abstract]. J Clin Oncol. 2008;26S. Abstract 8506.
20. Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin's disease with Adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975;36:252-259.
21. Horning SJ. Risk, cure and complications in advanced Hodgkin disease. Hematol Am Soc Hematol Educ Program. 2007;2007:197-203.